Clinical trials: Healthy Japanese Adult Male
Japanese Healthy Adult Male Participants
A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of a single dose of E6130 in Japanese healthy adult male participants.
- Trial name
- NCT02902978
- Testing
- E6130
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- EA Pharma Co., Ltd.
Embolism, Atrial Fibrillation and Venous Thrombosis
Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects
The objectives of this study are to establish the bioequivalence between rivaroxaban tablet 10mg and rivaroxaban granule formulation 10mg, and to assess the safety and tolerability of rivaroxaban 10mg in healthy adult male…
- Trial name
- NCT02537405
- Testing
- Rivaroxaban (BAY 59-7939), Rivaroxaban (Xarelto, BAY 59-7939)
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Coronavirus Disease (COVID-19)
A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
TAK-919 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-919 can protect people from Covid-19 and to check for side effects from TAK-919.
- Trial name
- NCT04677660
- Testing
- TAK-919
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single- and multiple-dose oral administration of JNJ-67953964 in healthy Japanese adult male participants.
- Trial name
- NCT04791332
- Testing
- JNJ-67953964
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Healthy Subjects
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects
This study is primarily designed to bridge the pharmacokinetics (PK) and safety data for E2609 between Japanese subjects and non-Japanese (ie, white) subjects.
- Trial name
- NCT02207790
- Testing
- E2609
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Volunteers
Single-Dose Study of MT203
The purpose of this study is to evaluate safety, pharmacokinetics and pharmacodynamics of single subcutaneous injection of MT203 in healthy adult Japanese and Caucasian male participants.
- Trial name
- NCT02354599
- Where
- Japan
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Takeda
Parkinson Disease
A Phase I Study of TRN501 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TRN501 following a single administration of TRN501 or placebo to healthy adult male volunteers.
- Trial name
- NCT06453551
- Testing
- TRN501 - Dose 1, TRN501 - Dose 2, TRN501 - Dose 3
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- SNLD, Ltd.
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Researchers in this study want to learn about the safety of drug BAY1817080 at different doses and the resulting blood levels of the study drug in Japanese healthy adult male participants.
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04265781
- Testing
- BAY1817080
- Where
- Japan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Japanese Male Adults
Phase I Trial Evaluating Safety and Tolerability of CAIV-T in Healthy Japanese Male Adults
The primary objective of the study was to investigate the safety and tolerability of CAIV-T liquid formulation in healthy Japanese male adults.
- Trial name
- NCT00224783
- Testing
- CAIV-T
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Coronavirus Disease (COVID-19)
A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019 for participants who will…
- Trial name
- NCT05299359
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Volunteers
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants
The purpose of this study is to evaluate the PK, safety and tolerability of phenylacetate and benzoate after intravenous administration of TAK-123 in Japanese healthy adult male participants.
- Trial name
- NCT04155567
- Testing
- TAK-123
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
A Study of Macitentan, in Healthy Japanese Male Participants
The main purpose of this study is to evaluate the safety and tolerability after multiple-dose administrations of macitentan with titration regimen starting from Dose 1 once daily (qd) up to Dose 2 qd in Japanese healthy adult…
- Trial name
- NCT04500808
- Testing
- Macitentan Dose 1, Macitentan Dose 2, Macitentan Dose 3
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.
Japanese Healthy Adult Males
A Bioequivalence Study of TAK-536 Pediatric Formulation
The purpose of this study is to evaluate the bioequivalence of a single oral dose of 2 different drug forms of TAK-536 pediatric formulation and a single oral dose of TAK-536 commercial tablet in healthy Japanese adult male…
- Trial name
- NCT02401464
- Testing
- TAK-536 Tablet, TAK-536 Dry Syrup Formulation, TAK-536 Ganule Formulation
- Where
- Japan
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and it is removed from the body over time) of single doses of…
- Trial name
- NCT01081821
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Clinical Pharmacology
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 10 mg in Japanese Healthy Male Adult Subjects
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 10 mg in Japanese healthy…
- Trial name
- NCT04511611
- Testing
- Rivaroxaban (BAY 59-7939, Xarelto) in ODT form, Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
- Where
- 3 sites in Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bayer
Japanese Healthy Adult Male Participants
A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation
The purpose of this study is to evaluate the bio-equivalence of a single oral administration of TAK-536 pediatric formulation (granules) in comparison with a TAK-536 commercial formulation (tablet) in Japanese healthy adult male…
- Trial name
- NCT03042299
- Testing
- TAK-536
- Where
- Japan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy Adult Male
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 To assess…
- Trial name
- NCT04182958
- Testing
- (14C)-OPC-61815
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Clinical Pharmacology
Study to Compare the Effect of the Formulations (Orally Disintegrating Tablet and Film-coated Tablet) on the Bioequivalence of Drug Rivaroxaban (Xarelto) at Dose of 15 mg in Japanese Healthy Male Adult Subjects
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 15 mg in Japanese healthy…
- Trial name
- NCT04511637
- Testing
- Rivaroxaban (BAY 59-7939, Xarelto) in ODT form, Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
- Where
- 3 sites in Japan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Volunteer
A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects
To determine the pharmacokinetic bioequivalence of DMB-3113 and adalimumab and to confirm the safety of the study drug in healthy Japanese adult male subjects
- Trial name
- DMB-3113-1 (NCT02927353)
- Testing
- DMB-3113, Adalimumab
- Where
- Japan
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Healthy
A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants
The purpose of this study is to evaluate the pharmacokinetics (PK) of rilpivirine/Tenofovir/Emtricitabine (RPV/TFV/FTC) after a single-oral administration of Complera (the fixed-dose combination of RPV, FTC, Tenefovir disoproxil…
- Trial name
- NCT02530060
- Testing
- Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC
- Where
- Japan
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Janssen Pharmaceutical K.K.